Hyperthyroidism - an unusual feature of thyroid carcinoma by Ekpebegh, Chukwuma O et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=oemd20
Download by: [University of Cape Town Libraries] Date: 11 January 2016, At: 01:18
Journal of Endocrinology, Metabolism and Diabetes of
South Africa
ISSN: 1608-9677 (Print) 2220-1009 (Online) Journal homepage: http://www.tandfonline.com/loi/oemd20
Hyperthyroidism—an unusual feature of thyroid
carcinoma
Chukwuma O Ekpebegh FMCP, Ian L Ross FCP & Naomi S Levitt MD
To cite this article: Chukwuma O Ekpebegh FMCP, Ian L Ross FCP & Naomi S Levitt MD
(2006) Hyperthyroidism—an unusual feature of thyroid carcinoma, Journal of Endocrinology,
Metabolism and Diabetes of South Africa, 11:2, 80-83, DOI: 10.1080/22201009.2006.10872147
To link to this article:  http://dx.doi.org/10.1080/22201009.2006.10872147
© 2006 SEMDSA. Published by Medpharm.
Published online: 12 Aug 2014.
Submit your article to this journal 
Article views: 12
View related articles 
80
JE
M
D
S
A
N
ov
em
b
er
 2
00
6,
 V
ol
. 
11
, 
N
o.
 2
Case description
A 53-year-old woman presented with a painless 
swelling of the left parieto-occipital scalp region of 
6 months’ duration. Painless thyromegaly had been 
noted a month before presentation. Besides significant 
weight loss, there were no overt symptoms of 
thyrotoxicosis. There was no personal or family history 
of autoimmune disease, and prior head and neck 
irradiation was not elicited.  
Examination revealed marked cachexia, sinus 
tachycardia of 105/min and a non-tender, soft left 
parieto-occipital scalp mass measuring 10 x 12 cm. 
She had moderate thyromegaly (30 g), which was hard 
in consistency, with a bruit and lymphadenopathy 
of the bilateral anterior triangles of the neck. There 
were no features of Graves’ ophthalmopathy or 
dermopathy. An additional finding was left lower lung 
consolidation.
Thyroid function test results were consistent with 
frank primary hyperthyroidism: free thyroxine 
(FT4) 46.3 pmol/l (normal 10.3 - 21.9 pmol/l) and 
thyrotropin (TSH) 0.01 IU/l (normal 0.35 - 4.5 IU/l). 
Anti-thyroglobulin and anti-thyroid peroxidase 
autoantibodies were negative. A Trucut biopsy 
of the scalp mass was performed. Histological 
review demonstrated well-formed thyroid follicles 
with occasional nuclear atypia and pleomorphism 
indicating metastatic follicular thyroid carcinoma. 
A whole-body technetium scan revealed uptake 
in multiple bony sites, liver, lung parenchyma and 
the rim of the scalp mass but minimal uptake in 
the thyroid gland. The patient had received Lugol’s 
iodine for the control of hyperthyroidism prior to 
the technetium scan, which interfered with the 
interpretation of this investigation. A chest radiograph 
showed infiltrations in the left lung (Fig. 1), suggestive 
of metastasis. Computed tomography of the skull 
showed full-thickness erosion of the left parietal and 
occipital skull bones with intracranial extension of the 
scalp mass (Fig. 2).
The diagnosis of functional metastatic thyroid 
carcinoma was based on the finding of follicular 
carcinoma on histological examination of the scalp 
mass and hyperthyroidism.
Hospital course    
We attempted to render the patient euthyroid 
to permit a safe total thyroidectomy. She was 
commenced on 40 mg daily of carbimazole and 
Lugol’s iodine was initiated 6 hours after the 
first dose of carbimazole. A Jod-Basedow effect 
(induction or exacerbation of thyrotoxicosis following 
administration of iodine in the presence of a goitre 
and iodine deficiency) occurred within 5 days of 
commencing Lugol’s iodine, with FT4 levels surging 
from 46.3 pmol/l to 80 pmol/l. This response to Lugol’s 
iodine was unexpected. In response to the dramatic 
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A 53-year-old woman presented with thyrotoxicosis, which is an unusual manifestation of thyroid carcinoma. 
Hyperthyroidism associated with malignancy usually occurs with well-differentiated follicular thyroid 
carcinoma. We show that extensive disease burden contributed to the development of hyperthyroidism, the 
occurrence of the Jod-Basedow phenomenon and the subsequent death of the patient. This diagnosis and 
treatment can be challenging.
Fig. 1. Chest radiograph showing widespread infiltration in the 
left lung with minimal pleural effusion.
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rise in FT4, Lugol’s iodine was withdrawn and the 
dose of carbimazole escalated to 65 mg daily, which 
was well tolerated. As she remained biochemically 
thyrotoxic, despite the latter intervention, we 
administered dexamethasone 6 mg daily in divided 
doses, propranolol 60 mg daily, lithium carbonate 
500 mg daily and cholestyramine 4 g daily. Iopodate, 
which is useful for rapid restoration of euthyroidism, 
was considered but is not available in our setting. 
Euthyroidism was achieved about 39 days after 
initial medical therapy and a total thyroidectomy was 
performed. An ablative dose of radioactive iodine 
was planned to eradicate thyroid bed remnants and 
metastases, but as she had received Lugol’s iodine, 
this intervention was to be deferred. We anticipated 
performing surgery and external radiation to the 
skeletal metastases and finally lifelong T4 therapy 
aimed at suppressing serum TSH levels to < 0.1 mIU/l 
to reduce disease recurrence. The patient died 14 
days after total thyroidectomy, before administration 
of radioactive iodine and surgery to the scalp mass. 
We believe that the cause of death was related to 
extensive tumour burden manifesting with extra-
thyroidal and in particular intracranial metastases.
Discussion
Thyrotoxicosis is an unusual manifestation of thyroid 
carcinoma. It typically occurs with differentiated 
thyroid carcinoma, as in our patient. A review of 
924 cases of thyroid carcinoma reported 19 (2.1%) 
with thyrotoxicosis; 15 had follicular and 4 papillary 
carcinoma.1 In a 20-year audit of 223 cases of thyroid 
carcinoma at this institution only 2 (0.9%) were toxic, 
both of whom had follicular thyroid carcinoma (I L 
Ross – unpublished observation, 2004).
The common causes of thyrotoxicosis in thyroid 
malignancy are coexisting Graves’ disease, nodular 
goitre and thyroid carcinoma per se.1,2 The presence 
of the bruit over the thyroid gland, a characteristic 
feature of Graves’ disease, was the sole suggestion 
of this latter diagnosis; however, as the thyroid 
gland was hard and craggy, this diagnosis was 
less likely. In addition the patient exhibited no 
associated ophthalmopathy, dermopathy or positive 
antithyroperoxidase and antithyroglobulin antibodies. 
Thyroid autoantibodies are, however, only positive 
in 75 - 80% of cases.3 The assay for TSH receptor 
antibody, which is a much more specific marker of 
Graves’ disease, is not available in our setting. Graves’ 
disease as a cause of thyrotoxicosis in metastatic 
thyroid carcinoma is remarkable because the TSH 
receptor antibodies resulting from autoimmune 
dysregulation still retain the ability to stimulate 
differentiated metastatic thyroid cancer cells after a 
total thyroidectomy.4 The presence of a bruit over the 
thyroid gland and its hard consistency also made the 
diagnosis of a toxic multinodular goiter highly unlikely. 
Although functional thyroid metastases may cause low 
thyroidal iodine uptake,5,6 the low uptake of technetium 
in our patient is confounded by prior treatment with 
Lugol’s iodine. Follicular destruction of the thyroid 
gland by the malignant process may also result in 
diminished thyroidal technetium uptake. In one series 
of 48 cases of toxic thyroid carcinoma,7 large tumour 
bulk is the factor most consistently associated with 
toxicity. The multiple sites of technetium uptake in 
our patient not only suggest functional metastates but 
are indicative of large tumour burden. 
Iopadate inhibits both thyroidal uptake of iodine 
and release of thyroid hormones, in addition to 
suppressing the conversion of FT4 to free thyroxine 
(FT3).
8 It would have represented the treatment of 
choice, but its lack of availability in our setting 
precluded its use. Dexamethasone and propranolol 
suppress the conversion of FT4 to FT3.
9,10  Propranolol 
has the additional benefit of non-selective beta-
receptor blockade.10 Lithium inhibits the release 
of thyroid hormone from the thyroid gland11 and 
cholestyramine interferes with the enterohepatic 
circulation, of FT4 and FT3.
12 Radioactive iodine 
therapy in the excessively thyrotoxic phase is not 
advisable, as mortality has been reported from further 
exacerbation of thyrotoxicosis.13 The occurrence of 
the Jod-Basedow effect shortly after starting Lugol’s 
iodine was unexpected, despite prior carbimazole 
administration. Multiple metastatic sites competing 
for iodine probably precipitated this. 
This patient’s age of over 40 years, the large size 
of the primary tumour and extensive metastases, 
in particular intracranial metastases,14,15 conferred 
an extremely poor prognosis. Brain metastasis from 
Fig. 2. CT scan showing erosion of left occipital and parietal skull 
bones with intracranial extension of scalp mass.
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thyroid malignancy is not only unusual16 but extremely 
ominous.17
Conclusion
Thyrotoxicosis is an unusual manifestation of thyroid 
malignancy and usually occurs with differentiated 
follicular carcinoma. It is a recognised cause of 
thyrotoxicosis with low thyroidal uptake of iodine 
on nuclear uptake scanning. A large tumour burden 
is the single factor most commonly associated with 
thyrotoxicosis. The complexities in the management 
of toxic thyroid carcinoma have been highlighted in 
this very unusual clinical presentation.
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